Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03282227 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Zosano Pharma Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 342
- Enrollment target
NCT03282227 is a Phase 3 study that has completed, run by Zosano Pharma Corporation. The registered enrollment target is 342 participants.
The verdict
NCT03282227, a Phase 3 study, has completed, sponsored by Zosano Pharma Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 342 participants
- Enrollment target
Study Summary
This is an open-label, twelve-month safety study. There is a screening period followed by a run-in period to record migraine activity. Qualified subjects will receive study medication for up to twelve months for the treatment of multiple migraine attacks. Using the electronic diary (eDiary) to confirm they are experiencing a qualified migraine, subjects will self-administer the patches and respond to questions in the eDiary post treatment administration.
Interventions
- DRUG M207 Microneedle System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2017-11-07 |
| Est. Completion | 2019-05-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03282227
The ClinicalTrials.gov registry entry for NCT03282227 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zosano Pharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which M207 Microneedle System is the first listed.
NCT03282227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03282227 about?
NCT03282227 is a clinical study titled "A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine". This is an open-label, twelve-month safety study. There is a screening period followed by a run-in period to record migraine activity. Qualified subjects will receive study medication for up to twelve months for the treatment of multiple migraine attacks. Using the electronic diary (eDiary) to confi...
What is the current status of trial NCT03282227?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 342 participants. The study started on 2017-11-07. Estimated completion is 2019-05-17.
What interventions are being tested in trial NCT03282227?
The interventions under investigation include: M207 Microneedle System (DRUG).
Who is sponsoring clinical trial NCT03282227?
This trial is sponsored by Zosano Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.